VIENNA — An investigational drug combination had high efficacy among patients with cirrhosis associated...
Read More
With Merck & Co. poised to disrupt competitors with new hepatitis C drugs, rivals...
Results of trials of antivirals to treat hepatitis C infections are dominating the proceedings...
The use of interferon to treat hepatitis C infections has fallen out of favor...
VIENNA — Patients with cirrhosis as well as genotype 1 and genotype 3 HCV...
VIENNA — Twenty-four weeks of treatment with Harvoni yielded a 12-week sustained virologic response...
UT Health Science Center San Antonio doctor presents results of daclatasvir regimen SAN ANTONIO...
Merck & Co. said Friday that its experimental drug combination for treating chronic hepatitis...
A number of new, highly effective oral treatments for various types of hepatitis C...
